Welcome to our dedicated page for Humacyte SEC filings (Ticker: HUMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humacyte, Inc. filings document a commercial-stage biotechnology issuer built around acellular tissue engineered vessels and related bioengineered human tissue programs. Its reports and 8-K filings cover operating results, product commercialization, clinical and regulatory disclosures, material agreements for Symvess distribution rights, and collaboration or licensing arrangements.
The company’s SEC record also includes capital-structure disclosures for common stock and redeemable warrants, equity offering arrangements, secured debt financing, and Nasdaq listing-rule notices. Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and other governance disclosures for HUMA.
Humacyte, Inc. plans to sell up to $60,000,000 of common stock through an at‑the‑market program with TD Securities (USA) LLC (TD Cowen), which will act as sales agent on Nasdaq and other trading markets. Humacyte will compensate TD Cowen with a commission of up to 3% of the gross sales price on any shares sold.
The company expects to use any net proceeds to fund commercialization of its FDA‑approved Symvess product for the vascular trauma indication, advance additional bioengineered tissue product candidates, and for working capital and general corporate purposes. Humacyte reports 158,835,303 shares of common stock outstanding as of September 30, 2025, and illustrates issuance of additional shares under the program, which would dilute existing holders. The broader shelf registration explains that, because existing cash and an equity facility will not fund operations for more than one year beyond the relevant filing date without new capital, there is substantial doubt about the company’s ability to continue as a going concern, underscoring the importance of external financing like this offering.
Humacyte, Inc. entered into a senior secured term loan facility of up to $77,500,000 maturing on December 1, 2029 with Avenue Venture Opportunities Fund II, L.P. The facility includes a $40 million first tranche funded at closing, a $12.5 million delayed draw available between October 1, 2026 and March 31, 2027 subject to revenue, regulatory and liquidity conditions, and a $25 million delayed draw available between July 1, 2027 and June 30, 2028 at the lenders’ discretion, also subject to conditions.
The term loans bear interest at the greater of 11.50% or the Wall Street Journal Prime Rate plus 4.50%, with interest-only payments and principal amortization starting December 1, 2027 or, if the second tranche is drawn, December 1, 2028. Humacyte granted Avenue a warrant expiring December 15, 2030 to purchase shares of common stock based on up to $5,037,500 divided by an exercise price set as the lower of $1.28 or the lowest cash sale price in certain equity offerings through March 31, 2026, subject to adjustments, and lenders may convert up to $2,500,000 of loan principal into common stock at 130% of the warrant price. The loans are secured by substantially all assets, carry 3%, 2% or 1% prepayment premiums depending on timing, and proceeds may be used for working capital, general business needs and repayment of existing indebtedness.
Humacyte, Inc. will issue 5,725,190 shares of common stock and pay $38 million in cash to end a revenue interest purchase agreement and a related option agreement with certain investment funds, in satisfaction of all obligations under those contracts.
The $38 million payment is expected to be funded with proceeds from a new credit facility, while the shares will be issued in a registered direct offering under an existing shelf registration statement. The offering is expected to close on December 15, 2025, subject to customary closing conditions.
Humacyte, Inc. reported that it has terminated its Open Market Sale Agreement™ with Jefferies LLC. This agreement had allowed the company to offer and sell shares of its common stock from time to time, with an aggregate offering price of up to $80,000,000 through Jefferies acting as sales agent. The company delivered a notice of termination on November 21, 2025, and the termination becomes effective 10 days after that date. Humacyte states that it is not subject to any termination penalties in connection with ending this agreement.
Humacyte, Inc. (HUMA) reported an equity award to a senior executive. The company’s CFO and Chief Corporate Development Officer, Dale A. Sander, reported acquiring 311,100 shares of Humacyte common stock on 11/16/2025 at a reported price of $0, reflecting a grant rather than an open-market purchase. Following this transaction, he beneficially owns 313,100 shares directly and 40,600 shares indirectly through his spouse.
The filing explains that these shares relate to restricted stock units (RSUs). The RSUs represent the right to receive one share of common stock for each unit, with 50% scheduled to vest on May 15, 2026 and the remaining 50% on May 15, 2027. This structure ties a significant portion of the executive’s compensation to the company’s future share performance over a two-year vesting period.
Humacyte, Inc. (HUMA) reported an equity award to its Chief Medical Officer, Shamik J. Parikh, on a Form 4. On 11/16/2025, Parikh acquired 311,100 shares of Humacyte common stock at a stated price of $0, linked to a grant of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of common stock. The first 50% of these RSUs will vest on May 15, 2026, with the remaining 50% vesting on May 15, 2027, subject to the award’s conditions. Following this reported transaction, Parikh beneficially owns 318,600 shares of Humacyte common stock, held directly.
Humacyte, Inc. (HUMA) reported a Form 4 for a director showing an indirect grant of stock options held by the director’s spouse. On 11/16/2025, the spouse acquired 311,100 stock options$1.23 per share
According to the vesting schedule, the first one-third of the options becomes exercisable on February 14, 2026, the next one-third on November 16, 2026, and the final one-third on November 16, 2027. Following this grant, the reporting person indirectly beneficially owns 311,100 derivative securities through the spouse.
Humacyte, Inc. (HUMA) reported a stock option award to its President, CEO and Director, Laura E. Niklason. On November 16, 2025, she was granted stock options to purchase 311,100 shares of Humacyte common stock at an exercise price of $1.23 per share, expiring on November 16, 2035. The options vest in three equal installments: one-third becomes exercisable on February 14, 2026, another third on November 16, 2026, and the final third on November 16, 2027. Following this grant, she holds these derivative securities directly.
Humacyte (HUMA) filed its Q3 2025 report, showing early commercialization of Symvess. Total Q3 revenue was $753 (in thousands), including $703 from product sales and $50 from contracts. Cost of goods sold was $260. Operating expenses declined year over year, with R&D at $17,273 and SG&A at $7,610. Loss from operations narrowed to $(24,390), and net loss improved to $(17,510), helped by gains in fair-value items.
Year to date, revenue reached $1,571, while the net loss was $(16,029). Cash and cash equivalents were $19,488 at September 30, 2025. The company amended its Revenue Interest Purchase Agreement and made a $50.0 million repayment using previously restricted cash, eliminating that restriction as of quarter-end. Management believes cash on hand and remaining capacity under its equity line are sufficient for at least twelve months from issuance.
The company began capitalizing Symvess inventory in early 2025, recording $18.4 million as of quarter-end. Availability remained under financing programs, with $47.5 million left on the equity line and $62.7 million under the ATM facility.
Humacyte, Inc. furnished an 8‑K announcing that it issued a press release with financial results for its fiscal third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference. The company states the information under Item 2.02, including the exhibit, is furnished and not deemed “filed” under the Exchange Act.
Humacyte’s securities trade as HUMA (common stock) and HUMAW (warrants) on Nasdaq.